Programs around an FDA decision. Across oncology, rare disease, gene & cell therapy, and other specialty indications.

Coverage is organized around indications in which the pre-commercial vendor decision space is dense, the signal environment is legible from public sources, and the timing of engagement materially affects launch outcomes. Indications outside active coverage can be prepared as a custom brief within 48 hours of an initial conversation.